JP5342451B2 - Ｐｄｅ４阻害剤として有用な置換アセトフェノン - Google Patents

Ｐｄｅ４阻害剤として有用な置換アセトフェノン Download PDF

Info

Publication number
JP5342451B2
JP5342451B2 JP2009541766A JP2009541766A JP5342451B2 JP 5342451 B2 JP5342451 B2 JP 5342451B2 JP 2009541766 A JP2009541766 A JP 2009541766A JP 2009541766 A JP2009541766 A JP 2009541766A JP 5342451 B2 JP5342451 B2 JP 5342451B2
Authority
JP
Japan
Prior art keywords
compound
pyridin
dichloro
dimethoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513334A (ja
JP2010513334A5 (cg-RX-API-DMAC10.html
Inventor
ヤコブ・フェルディング
シモン・フェルドベク・ニルセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of JP2010513334A publication Critical patent/JP2010513334A/ja
Publication of JP2010513334A5 publication Critical patent/JP2010513334A5/ja
Application granted granted Critical
Publication of JP5342451B2 publication Critical patent/JP5342451B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009541766A 2006-12-22 2007-12-21 Ｐｄｅ４阻害剤として有用な置換アセトフェノン Expired - Fee Related JP5342451B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87168906P 2006-12-22 2006-12-22
US60/871,689 2006-12-22
US94547007P 2007-06-21 2007-06-21
US60/945,470 2007-06-21
PCT/DK2007/000564 WO2008077404A1 (en) 2006-12-22 2007-12-21 Substituted acetophenones useful as pde4 inhibitors

Publications (3)

Publication Number Publication Date
JP2010513334A JP2010513334A (ja) 2010-04-30
JP2010513334A5 JP2010513334A5 (cg-RX-API-DMAC10.html) 2013-08-22
JP5342451B2 true JP5342451B2 (ja) 2013-11-13

Family

ID=39156588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541766A Expired - Fee Related JP5342451B2 (ja) 2006-12-22 2007-12-21 Ｐｄｅ４阻害剤として有用な置換アセトフェノン

Country Status (23)

Country Link
US (3) US8148537B2 (cg-RX-API-DMAC10.html)
EP (1) EP2125736B1 (cg-RX-API-DMAC10.html)
JP (1) JP5342451B2 (cg-RX-API-DMAC10.html)
KR (1) KR101507717B1 (cg-RX-API-DMAC10.html)
AT (1) ATE503742T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007336538B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0721113A2 (cg-RX-API-DMAC10.html)
CA (1) CA2673370C (cg-RX-API-DMAC10.html)
CR (1) CR10877A (cg-RX-API-DMAC10.html)
CY (1) CY1111596T1 (cg-RX-API-DMAC10.html)
DE (1) DE602007013617D1 (cg-RX-API-DMAC10.html)
DK (1) DK2125736T3 (cg-RX-API-DMAC10.html)
GT (1) GT200900172A (cg-RX-API-DMAC10.html)
HR (1) HRP20110464T1 (cg-RX-API-DMAC10.html)
IL (1) IL199383A (cg-RX-API-DMAC10.html)
MX (1) MX2009006593A (cg-RX-API-DMAC10.html)
MY (1) MY146022A (cg-RX-API-DMAC10.html)
NO (1) NO20092372L (cg-RX-API-DMAC10.html)
NZ (1) NZ577863A (cg-RX-API-DMAC10.html)
PL (1) PL2125736T3 (cg-RX-API-DMAC10.html)
PT (1) PT2125736E (cg-RX-API-DMAC10.html)
RU (1) RU2493149C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008077404A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012007234A (es) 2009-12-22 2012-07-30 Leo Pharma As Nanocristales de monohidrato de calciprotiol.
RU2560677C2 (ru) 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
MX2012007225A (es) 2009-12-22 2012-07-30 Leo Pharma As Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
WO2014083099A1 (en) * 2012-11-30 2014-06-05 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
WO2014096018A1 (en) * 2012-12-19 2014-06-26 Leo Pharma A/S Methods for the preparation of substituted acetophenones
AU2014339136C1 (en) * 2013-10-22 2019-10-31 Chiesi Farmaceutici S.P.A. Process for the preparation of a PDE4 inhibitor
JP6785666B2 (ja) 2014-06-23 2020-11-18 レオ ファーマ アクティーゼルスカブ １，３−ベンゾジオキソール複素環化合物の調製方法
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
DK3390407T3 (da) 2015-12-18 2023-11-06 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
KR101702648B1 (ko) * 2016-05-10 2017-02-03 주식회사 엑티브온 피부 외용제용 보존제, 이를 포함하는 화장료 조성물 및 약학 조성물
AU2018286964B2 (en) 2017-06-20 2022-04-14 UNION therapeutics A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EP3838967A1 (en) 2019-12-16 2021-06-23 Spago Nanomedical AB Immobilization of phenolic compounds
CN117924243B (zh) * 2024-01-16 2025-09-12 沈阳药科大学 一种喹啉衍生物及其药用组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (cg-RX-API-DMAC10.html) * 1992-12-23 1995-11-21 Celltech Ltd
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
HK1000785A1 (en) * 1995-05-19 2006-06-30 Kyowa Hakko Kogyo Co., Ltd Oxygen-containing heterocyclic compounds
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
AU4967697A (en) * 1996-11-19 1998-06-10 Kyowa Hakko Kogyo Co. Ltd. Oxygenic heterocyclic compounds
EP1621196A4 (en) * 2003-03-17 2007-03-21 Kyowa Hakko Kogyo Kk THERAPEUTIC AND / OR PREVENTIVE AGENT FOR CHRONIC SKIN DISEASES
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
US20070049611A1 (en) * 2005-06-10 2007-03-01 Talamas Francisco X Phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
US8497380B2 (en) 2013-07-30
DE602007013617D1 (de) 2011-05-12
CY1111596T1 (el) 2015-10-07
KR101507717B1 (ko) 2015-04-08
US20130012716A1 (en) 2013-01-10
HK1135392A1 (en) 2010-06-04
MX2009006593A (es) 2009-07-02
CA2673370A1 (en) 2008-07-03
JP2010513334A (ja) 2010-04-30
HRP20110464T1 (hr) 2011-07-31
ATE503742T1 (de) 2011-04-15
BRPI0721113A2 (pt) 2014-10-07
KR20090098990A (ko) 2009-09-18
US20100035908A1 (en) 2010-02-11
NZ577863A (en) 2012-04-27
GT200900172A (es) 2011-10-05
NO20092372L (no) 2009-07-14
US8148537B2 (en) 2012-04-03
US20120165539A1 (en) 2012-06-28
PT2125736E (pt) 2011-07-01
RU2009128191A (ru) 2011-01-27
CA2673370C (en) 2015-11-17
DK2125736T3 (da) 2011-07-11
PL2125736T3 (pl) 2011-09-30
AU2007336538A1 (en) 2008-07-03
IL199383A (en) 2015-02-26
RU2493149C2 (ru) 2013-09-20
MY146022A (en) 2012-06-15
US8324394B2 (en) 2012-12-04
WO2008077404A1 (en) 2008-07-03
AU2007336538B2 (en) 2012-04-05
EP2125736B1 (en) 2011-03-30
EP2125736A1 (en) 2009-12-02
CR10877A (es) 2009-07-10

Similar Documents

Publication Publication Date Title
CA2673370C (en) Substituted acetophenones useful as pde4 inhibitors
JP7519221B2 (ja) 置換ピラゾロ［１，５－ａ］ピリミジンおよび医療疾患の治療におけるその使用
NL1028947C2 (nl) Gesubstitueerde methylaryl- of heteroarylamideverbindingen.
JP4054369B2 (ja) オルト置換アリールまたはヘテロアリールアミド化合物
DE69403823T2 (de) Substituierte Phenylsulfonamine als selektive B3-Agonisten zur Behandlung von Diabetes und Fettleibigkeit
JP4116058B2 (ja) プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物
JP2004532229A (ja) 脂肪酸アミド加水分解酵素阻害剤
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
ES2363565T3 (es) Acetofenonas sustituidas útiles como inhibidores de pde4.
CN101522674B (zh) 作为香草酸受体拮抗剂的新化合物或其药物学可接受的盐、及包含这些化合物的药物组合物
TWI429433B (zh) 可供治療使用之經取代苯乙酮化物
HK1135392B (en) Substituted acetophenones useful as pde4 inhibitors
AU2012203892A1 (en) Substituted acetophenones useful as PDE4 inhibitors
RS51736B (sr) Supstituisani acetofenoni korisni kao inhibitori pde4
CN120865048A (zh) Mas相关g蛋白受体x4调节剂及用途
JP2007511501A (ja) グルココルチコイド受容体調節剤として有用なオクタヒドロフェナンスレンヒドラジド誘導体
MXPA06009198A (en) Therapeutic amide derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101005

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130613

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130809

R150 Certificate of patent or registration of utility model

Ref document number: 5342451

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees